Bayer has added another phase 3 trial into its registration programme for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixed results in phase 2.

View the profiles of professionals named "Yu Xia" on LinkedIn. There are 30+ professionals named "Yu Xia", who use LinkedIn to exchange information, ideas, and opportunities.

Contribute to 2461422342/http-xia.github.io development by creating an account on GitHub.